Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. Otsuka is a healthcare company driven by our purpose and defined by our beliefs. At Otsuka, we hold a deep respect for the value of every mind. residents only.

We believe that the human mind is infinitely valuable, fostering imagination, intelligence, perception, and so much more. By recognizing this value, we have the power to change the trajectory of people’s lives. This is why we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention. Through products, programs, policies, and advocacy, Otsuka-people will defy any limitation that stands in their way until every mind is valued. This commitment extends to those who care for people living with mental illnesses and other brain conditions. We are dedicated to caring for those who care for our patients—standing with them, the way they stand with their loved ones—and offering the tools they need for the health of others and themselves

----
There are two Otsuka pharmaceutical industry companies in the U.S.:

Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis

Learn more at www.otsuka-us.com

----
Community Guidelines:

Welcome to the Otsuka page. We're excited to have you be part of our Facebook community, and look forward to discussing a variety of topics. However, we'd like to remind you that healthcare is a regulated industry and, as such, we cannot engage in discussions about our products – or the products of other companies. With this in mind, we may not be able to respond to or comments that:
Mention products
Include profanity, defamatory or abusive comments
Offer health or medical advice
Are spam or are soliciting business
Violate Facebook's platform rules

Please keep in mind that this page is intended for U.S. Also, please note that Facebook accounts that the Otsuka handle follows, or are followed by, are not an indication of an endorsement by Otsuka feeds or the content they produce. With this in mind, comments made on third party feeds that the Otsuka handle follows do not necessarily represent the opinion of Otsuka America Pharmaceutical, Inc., or Otsuka Pharmaceutic Development & Commercialization, Inc. Medical Side Effects or Adverse Events
If you believe that you have experienced any medical side effects or reactions from an Otsuka product, you should consult your physician, pharmacist or other healthcare professional immediately. If you wish to report an adverse event associated with any of our products, please call us at 1-800-438-9927. The FDA also has a website where you can report side effects of prescription drugs at www.fda.gov/medwatch, or call 1-800-FDA-1088.

11/06/2025

Today, we are pleased to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) have successfully enrolled and dosed the first patients in its Phase 3 clinical trial evaluating quabodepistat, an investigational compound for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB).

Tuberculosis, and particularly its resistant forms, remains a major global health challenge. According to the World Health Organization, 10 million people fall ill with tuberculosis each year, most of whom live in low- to middle-income countries. Despite being preventable and curable, 1.25 million people die from the disease annually.

At Otsuka, we have a fierce determination to overcome obstacles with a goal to provide advanced care for patients. Our mission is clear. Otsuka-people: creating new products for better health worldwide.

Learn more: https://bit.ly/4p0g04a

11/05/2025

We are thrilled to support the American Society of Nephrology (ASN) Kidney Week 2025 Annual Meeting and look forward to engaging with kidney disease experts from across the world.

For those registered to attend, we invite you to join us at our Booth #1503 in the exhibit hall and at our Exhibitor Spotlight, "B-Cell Modulation in IgA Nephropathy", on Thursday, November 6 at 1:00PM CST.

Our perseverance and long-term commitment in the nephrology space has led to major breakthroughs, giving patients renewed hope and clinicians more options than ever before.

Discover our commitment at www.otsuka-us.com/nephrology

Otsuka is a supporter of the American Society of Nephrology (ASN) Kidney Week 2025 Annual Meeting. Only registered participants of the ASN meeting are eligible to attend as determined by the event organizer, ASN. Otsuka has no control over registration, or the fees associated.

10/31/2025

We are feeling grateful after our time spent at the October Mental Health America (MHA) 2025 Conference amongst other mental health advocates, organizations and affiliates.

Throughout the three-day conference, Otsuka-people Caroline Fisher O'Neill, Senior Director of Alliance Development, had the opportunity to provide welcome remarks at the Affiliate Day lunch; and Leigh Morrissey, Director of Public Policy, presented on a panel discussion featuring Otsuka's State Medicaid Open Access studies. Most notably, Tom Foulkes, Senior Director of Federal and State Government Affairs, presented the 2025 MHA Media Award to the Caregiving Documentary to director Chris Durrance, who accepted the award.

Thank you to our Otsuka attendees, specifically all of our colleagues in Government Affairs & Public Policy and Patient Advocacy Stakeholder Management (PASM).

Otsuka is a lead, founding sponsor of WETA's Caregiving documentary.
Otsuka sponsored the Mental Health America (MHA) 2025 Conference.

Join us for the final Attention Deficit Disorder Association (ADDA) Awareness Month webinar series on Wednesday, October...
10/29/2025

Join us for the final Attention Deficit Disorder Association (ADDA) Awareness Month webinar series on Wednesday, October 29.

Otsuka is a proud sponsor of Attention Deficit Disorder Association (ADDA) Awareness Month webinar series throughout October.

At Otsuka, we believe that the human mind is infinitely valuable, fostering imagination, intelligence, perception, and so much more. By recognizing this value, we have the power to change the trajectory of people’s lives.

Learn more about our commitment: otsuka-us.com/CNS

November 2025 01US25EUC0432

Joins us as Dr. Gurdeep Parhar discusses "The Emotional Compass of ADHD: Motivation, Shame, and Self-Perception" for the last webinar in ADDA's Awareness Month webinar series, sponsored by Otsuka.

Register here: http://evt.to/eooididew?utm_campaign=meetedgar&utm_medium=social&utm_source=meetedgar.com

This month, we attended and sponsored the ALS TDI Summit in Boston, MA, an event aimed to inform and empower the Amyotro...
10/28/2025

This month, we attended and sponsored the ALS TDI Summit in Boston, MA, an event aimed to inform and empower the Amyotrophic Lateral Sclerosis (ALS) community through educational and informative sessions.

At Otsuka, we aspire to bring hope to patients affected by neurodegenerative diseases, including ALS and other rare conditions, by advancing novel therapies that address areas of high unmet need.

Learn more about our commitment: www.otsuka-us.com/CNS
October 2025 01US25EUC0424

Last month, we proudly sponsored the 2025 Heroes in Health Celebration hosted by the Alliance for Aging Research at the ...
10/20/2025

Last month, we proudly sponsored the 2025 Heroes in Health Celebration hosted by the Alliance for Aging Research at the Waldorf Astoria in Washington, DC. The event brought together leaders and innovators in health policy and aging research to discuss critical topics like transparency in Medicare and aligning FDA policies with an aging population.

Otsuka leaders from across departments listened in on conversations with CMS and FDA leaders on improving health outcomes for older adult and had the opportunity to join as the Alliance presented awards to key leaders in the aging space. We are honored to collaborate with the Alliance for Aging Researchand ensuring safe medication use and healthy living for older adults.

Special thanks to our Otsuka attendees and those from the National Health Council and the National Hispanic Council on Aging (NHCOA) for joining with us.

At Otsuka, we remain committed to health for every mind.

10/15/2025

Otsuka is honored to sponsor the 2025 National Organization for Rare Disorders, Inc. (NORD) Rare Diseases & Orphan Products Breakthrough Summit in Washington, DC, October 19-21!

This premier event brings together medical experts, industry leaders, and patient advocates to advance progress. Visit us at Booth #10, to learn more about our commitment to the rare community.

Register here: https://NORDSummit.org

October 2025 01US25EUC0378

Otsuka is a proud sponsor of NORD. Only registered participants of the NORD Rare Diseases & Orphan Products Breakthrough Summit are eligible to attend as determined by the event organizer, NORD. Otsuka has no control over registration, or the fees associated.

Otsuka is a proud sponsor of Attention Deficit Disorder Association (ADDA) Awareness Month webinar series all month long...
10/15/2025

Otsuka is a proud sponsor of Attention Deficit Disorder Association (ADDA) Awareness Month webinar series all month long.

At Otsuka, we believe that the human mind is infinitely valuable, fostering imagination, intelligence, perception, and so much more. By recognizing this value, we have the power to change the trajectory of people’s lives.

Learn more about our commitment: otsuka-us.com/CNS

October 2025 01US25EUC090

Learn about the science behind ADHD from genetics to treatment outcomes. Join us as Stephen V. Faraone discusses “The Lifelong Reality of ADHD: What the Science Actually Shows” for ADDA's Awareness Month webinar series, sponsored by Otsuka.

Register here: http://evt.to/eooidihgw?utm_campaign=meetedgar&utm_medium=social&utm_source=meetedgar.com

10/15/2025

"The caregiving community is being stretched to the limits and clearly needs different kinds of support." — Debra Barrett, Vice President, Corporate Affairs, Otsuka America Pharmaceutical, Inc.

Debra Barrett and Jessica Guthrie, a family caregiver caring for her mother, sat down to discuss the caregiver crisis in the U.S. and highlight findings from the latest in a research series conducted by Columbia University Mailman School of Public Health, and sponsored by Otsuka America Pharmaceutical, Inc., called “America’s Unseen Workforce: The State of Family Caregiving”.

The report analyzed a multitude of factors at the state level to assess how differing demographics, healthcare infrastructures and economic conditions impact unpaid family caregivers. And includes an illustrative state-by-state heatmap based on a scorecard of the family caregiving landscape to raise awareness of the value of family caregivers and inform decision-making and political advocacy to support them.

The findings show unpaid family caregiving is either “critical” or at “high risk” in 24 states. Find out how your state scored: https://bit.ly/433vOdA

10/14/2025

This October, we're recognizing .

Known as attention-deficit hyperactivity disorder, ADHD is a neurodevelopmental disorder affecting 11% of school-age children and is characterized by developmentally inappropriate levels of inattention, impulsivity and hyperactivity. Symptoms may continue into adulthood for more than three out of four people diagnosed as children.

At Otsuka, our core values of perseverance, unconventional thinking and humility position us to lead in the development of the transformative potential of innovative therapies in mental healthcare.

Discover our commitment: https://bit.ly/489qTLG

September 2025 01US25EUC0135

10/10/2025

Every day, we work toward realizing our vision: health for every mind. In addition to pioneering treatments for people living with central nervous system conditions, we believe in advocating, educating, and collaborating to support the mental and neurological health of the communities we serve.

At Otsuka, we hold a deep respect for the value of every mind. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients and caregivers everywhere.

Discover our commitment: https://bit.ly/3WjLbL9

Affecting more than 21 million American adults each year, major depression is one of the most common mental illnesses in...
10/09/2025

Affecting more than 21 million American adults each year, major depression is one of the most common mental illnesses in the nation.

In support of National Depression Screening Day, let’s take the time to check in on our loved ones and take one of the first steps towards better health.

Like screenings for other illnesses, depression screenings should be no different and a routine part of healthcare.

Learn more now from Mental Health America: https://bit.ly/3IIkInC

Address

508 Carnegie Center
Princeton, NJ
08540

Alerts

Be the first to know and let us send you an email when Otsuka America Pharmaceutical, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram